Melphalan is used for: Breast cancer; Ovarian cancer; Multiple myeloma; Neuroblastoma; Soft tissue sarcoma; Malignant melanoma; Retinoblastoma; Polycythaemia vera.
Recorded in the NepalDoc medicine catalog for Melphalan.
HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
From the U.S. FDA-approved label for Melphalan. Full label: DailyMed.
HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
From the U.S. FDA-approved label for Melphalan. Full label: DailyMed.
HEPZATO, a component of the HEPZATO KIT, is administered by intra-arterial infusion into the hepatic artery (see instructions for use ). The recommended dose is 3 mg/kg based on ideal body weight (see Table 1 ), with a maximum absolute dose of 220 mg during a single HEPZATO treatment.. The drug is infused over 30 minutes followed by a 30-minute washout period (see IFU).
Directions from the U.S. FDA-approved label for Melphalan — your doctor or pharmacist may advise differently.
HEPZATO and the HEPZATO KIT are contraindicated in patients with: Active intracranial metastases or brain lesions with a propensity to bleed Liver failure, portal hypertension, or known varices at risk for bleeding Surgery or medical treatment of the liver in the previous 4 weeks Uncorrectable coagulopathy Inability to safely undergo general anesthesia, including active cardiac conditions including, but not limited to, unstable coronary syndromes (unstable or severe angina or myocardial infarction), worsening or new-onset congestive heart failure…
Excerpt from the U.S. FDA-approved label for Melphalan. Talk to a pharmacist or doctor before use.
Hypersensitivity reactions, including anaphylaxis, have occurred in patients who received an intravenous (IV) formulation of melphalan. Immediately terminate hepatic arterial melphalan infusion for hypersensitivity reactions and administer supportive care. Gastrointestinal disturbances such as nausea and vomiting, abdominal pain and diarrhea are common. Carcinogenic/Mutagenic effects: Secondary malignancies, including acute nonlymphocytic leukemia, myeloproliferative syndrome, and carcinoma, have been reported in patients with cancer treated with alkylating drugs (including melphalan).
Warnings and precautions excerpt from the U.S. FDA-approved label for Melphalan — not a complete list. Talk to a pharmacist or doctor before use.
Below are adverse reactions associated with HEPZATO KIT. Additional adverse reactions related to the procedure and/or medical device are described in further detail in the HEPZATO KIT IFU.
Excerpt from the U.S. FDA-approved label for Melphalan — not a complete list. Talk to a pharmacist or doctor about side effects.
HEPZATO for injection and its associated diluents including 0.9% sodium chloride must be stored at controlled room temperature 20°C to 25°C (68°F to 77°F). Temperature excursions are permitted between 15°C- 30°C (59°F-86°F). The Hepatic Delivery System components may be stored at room temperature. Melphalan is a hazardous drug.
Storage information from the U.S. FDA-approved label for Melphalan.
What is Alkeran 2?
Alkeran 2mg Tablet is a Melphalan medicine made by Glaxo SmithKline Pharmaceuticals Ltd. It comes as 2mg Tablet.
What is Alkeran 2 used for?
Melphalan is used for Breast cancer, Ovarian cancer, Multiple myeloma, Neuroblastoma, Soft tissue sarcoma, Malignant melanoma, Retinoblastoma, Polycythaemia vera.
What is the generic name of Alkeran 2?
The generic name of Alkeran 2 is Melphalan.
What are the side effects of Melphalan?
Below are adverse reactions associated with HEPZATO KIT. Additional adverse reactions related to the procedure and/or medical device are described in further detail in the HEPZATO KIT IFU.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
